EQRx, Inc.

EQRx, Inc., trading under the ticker CMLT, is a biopharmaceutical company that reached the public markets through a SPAC merger, with the blank-check vehicle having completed its IPO in 2021. The company operates in the healthcare and pharmaceutical sector, positioning itself around the development and commercialization of innovative medicines. An 8-K was filed with the SEC on August 1, 2023, under accession number 0001193125-23-199916, representing a current-report disclosure in the post-merger period. EQRx completed its de-SPAC transaction in 2022, transitioning from a development-stage structure to a publicly listed operating company. Investors and researchers tracking CMLT's regulatory filings and corporate developments can access full historical data, deal timelines, and filing archives by signing up for a SpacDesk account at SpacDesk.com.